Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
GlobalData on MSN11h
Amgen and Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpointsAll the key secondary endpoints of the trial were met, demonstrating the “statistical significance” of the therapy.
In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...
Zacks Investment Research on MSN9h
AMGN's Eczema Drug Meets Goal in Two Late-Stage StudiesAmgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET ...
Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints ...
Amgen (AMGN) and Kyowa Kirin (KYKOF) announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an ...
MedPage Today on MSN19h
T-Cell Rebalancing Therapy Active in Previously Treated Atopic DermatitisA novel therapy for atopic dermatitis (AD) led to at least 75% improvement in a third of patients after 6 months, a ...
Term Maintenance and Durability THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa ...
US biotech Amgen (Nasdaq: AMGN) and Japanese partner Kyowa Kirin (TYO: 4151) announced new results from the ongoing ROCKET ...
Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback